The significance of tumor necrosis factor (TNF) levels for rejection of joint allograft.
This paper describes the efficacy of utilizing Tumor Necrosis Factor-alpha (TNF) as a detectable parameter of acute rejection after bone allografts. The authors used a bone-joint allograft model, transferring vascularized allograft knee joints across a major histocompatibility barrier, using three groups of rats divided into controls, non-immunosuppressed, and immunosuppressed with cyclosporine. The paper supplies preliminary information suggesting that TNF may be a marker for early bone-joint allograft rejection.
Watanabe
H
H
Department of Orthopedic Surgery, Yamanashi Medical College, Japan.
Nagasawa
K
K
Hamada
Y
Y
Toshima
T
T
Sakano
Y
Y
Akamatsu
N
N
D000818:Animals; D015415:Biomarkers / Q000097:blood; D016025:Bone Transplantation / Q000473:pathology; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000097:blood* / Q000473:pathology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007719:Knee Joint / Q000601:surgery*; D051381:Rats; D011914:Rats, Inbred BN; D011916:Rats, Inbred F344; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D015415:Biomarkers; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine